Payment overview · 2025
General Payments
$2,718.59
175 reported records · 19 companies
Healthcare provider profile · identity verified
Joseph P Greco, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DUNMORE, PA · NPI 1881662567
Verified facts
What the public records show
CMS Open Payments records show Joseph P Greco, MD received $2,718.59 in general payments during 2025 across 175 reported records.
Novo Nordisk Inc accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $558.71 | 20.6% | 29 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $444.55 | 16.4% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $271.17 | 10.0% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $244.34 | 9.0% | 35 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $234.11 | 8.6% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $196.59 | 7.2% | 18 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $137.04 | 5.0% | 15 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $106.53 | 3.9% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $94.44 | 3.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $81.22 | 3.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.29 | 3.0% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $76.20 | 2.8% | 4 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.11 | 1.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.90 | 1.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $28.79 | 1.1% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $21.20 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.60 | 0.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.90 | 0.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.90 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,718.59 | 175 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $391.71 | 19 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $289.57 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $236.46 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $207.67 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $201.58 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $197.09 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $196.12 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $191.88 | 32 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $191.88 | 32 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $171.85 | 14 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $149.16 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $137.04 | 15 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $135.26 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $109.08 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $107.17 | 8 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $106.53 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $105.96 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $95.91 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $90.72 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $86.35 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $76.20 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $58.88 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $52.46 | 3 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $47.11 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $44.90 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $43.51 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $35.56 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.44 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.44 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.44 | 2 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $25.19 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 206 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 112 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
73 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
206 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 672 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 434 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 424 | 104 |
| Lisinopril | Lisinopril | 325 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 297 | 58 |
| Metformin Hcl | Metformin Hcl | 268 | 66 |
| Losartan Potassium | Losartan Potassium | 219 | 53 |
| Furosemide | Furosemide | 215 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 48 |
| Eliquis | Apixaban | 206 | 38 |
| Alprazolam | Alprazolam | 202 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 195 | 41 |
| Simvastatin | Simvastatin | 195 | 49 |
| Omeprazole | Omeprazole | 194 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 172 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 34 |
| Sertraline Hcl | Sertraline Hcl | 135 | 35 |
| Allopurinol | Allopurinol | 120 | 35 |
| Jardiance | Empagliflozin | 112 | 26 |
| Potassium Chloride | Potassium Chloride | 111 | 24 |
| Ozempic | Semaglutide | 108 | 17 |
| Gabapentin | Gabapentin | 98 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 22 |
| Lorazepam | Lorazepam | 93 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 14 |
| Synthroid | Levothyroxine Sodium | 73 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 17 |
| Benazepril Hcl | Benazepril Hcl | 66 | 16 |
| Tramadol Hcl | Tramadol Hcl | 66 | 21 |
| Metformin Hcl Er | Metformin Hcl | 59 | 18 |
| Glipizide | Glipizide | 57 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 16 |
| Glipizide Er | Glipizide | 54 | 13 |
| Alendronate Sodium | Alendronate Sodium | 53 | 11 |
| Lovastatin | Lovastatin | 52 | 16 |
| Carvedilol | Carvedilol | 50 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | suppressed |
| Clonazepam | Clonazepam | 48 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 48 | suppressed |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 14 |
| Pregabalin | Pregabalin | 47 | 11 |
| Methylprednisolone | Methylprednisolone | 46 | 39 |
| Felodipine Er | Felodipine | 44 | suppressed |
| Sotalol | Sotalol Hcl | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Famotidine | Famotidine | 39 | 12 |
| Atenolol | Atenolol | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 28 |
| Levofloxacin | Levofloxacin | 32 | 30 |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Prednisone | Prednisone | 23 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Dutasteride | Dutasteride | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Baclofen | Baclofen | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,718.59 · 175 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, ONPATTRO, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, RINVOQ, Rybelsus, SYNTHROID, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error